The use of six specific IHC markers—CD20, CD5, CD8, CD68, CD23, and CD45—is based on their established roles in lymphocyte differentiation, tumor microenvironment characterization, and specific disease pathologies relevant to the study's focus. Here, PTPRC is linked to neoplasm.